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Abstract
AIM
To evaluate the occurrence of resistant mutations in
treatment-naïve hepatitis C virus (HCV) sequences
deposited in the European hepatitis C virus database
(euHCVdb).
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METHODS
The sequences were downloaded from the euHCVdb
(https://euhcvdb.ibcp.fr/euHCVdb/). The search was
performed for full-length NS3 protease, NS5A and NS5B
polymerase sequences of HCV, separated by genotypes
1a, 1b, 2a, 2b and 3a, and resulted in 798 NS3, 708
NS5A and 535 NS5B sequences from HCV genotypes

Open-Access: This article is an open-access article which was
selected by an in-house editor and fully peer-reviewed by external
reviewers. It is distributed in accordance with the Creative
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1a, 1b, 2a, 2b and 3a, after the exclusion of sequences
containing errors and/or gaps or incomplete sequences,
and sequences from patients previously treated with
direct antiviral agents (DAA). The sequence alignment
was performed with MEGA 6.06 MAC and the resulting
protein sequences were then analyzed using the BioEdit
7.2.5. for mutations associated with resistance. Only
positions that have been described as being associated
with failure in treatment in in vivo studies, and/or as
conferring a more than 2-fold change in replication in
comparison to the wildtype reference strain in in vitro
phenotypic assays were included in the analysis.

Kliemann DA, Tovo CV, da Veiga ABG, de Mattos AA, Wood
C. Polymorphisms and resistance mutations of hepatitis C virus
on sequences in the European hepatitis C virus database. World
J Gastroenterol 2016; 22(40): 8910-8917 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v22/i40/8910.htm DOI:
http://dx.doi.org/10.3748/wjg.v22.i40.8910

INTRODUCTION
Chronic hepatitis C virus (HCV) infection affects around
180 million people worldwide and is a significant cause
[1]
of liver-related morbidity and mortality until recently.
Interferon-α in combination with Ribavirin was the
mainstream treatment regimen but eligibility and
safety of the interferon-based therapies were low, and
consequently the overall effectiveness of the treatment
was very limited. Fortunately, the development of new
direct-acting antiviral (DAA) drugs against HCV has
progressed significantly and resulted in oral interferon[2]
free therapies .
The three main therapeutic targets for HCV infection
are the NS3/4A protease, the NS5B polymerase,
and the NS5A replication complex. The first series
of interferon-free regimens, including combinations
of simeprevir (SMV), sofosbuvir (SOF), paritaprevir,
daclatasvir, ledipasvir (LDV), ombitasvir (OMV),
dasabuvir (DSV), grazoprevir (GZR) and elbasvir have
already been approved and recommended by the
European Association for the Study of the Liver (EASL)
and by the American Association for the Study of Liver
[3,4]
Diseases (AASLD) .
HCV variants infecting the human population show
extreme genetic diversity, which is partly explained by
the long evolutionary association between the virus
and its human host. HCV exists in the host as a swarm
of related quasispecies. This diversity is a result of
the error-prone viral polymerase combined with rapid
viral replication, which, in turn, enables the virus to
rapidly overcome the host immune responses and to
[5]
become resistant to antiviral drugs . The selection of
resistance-associated amino-acid variants (RAV) from
HCV quasispecies is dependent on drug-, host- and
virus-related factors. The potency of the drug itself is
primarily influenced by viral susceptibility, by previous
exposure to the drug and by the genetic barrier to
resistance. The ability of a RAV to persist and to induce
treatment failure (relapse, non-response or viral
breakthrough) is related to its fitness or its replication
[6,7]
capacity as compared to the wild-type virus .
Resistance to DAAs is driven by the selection of
mutations at different positions in the NS3 protease,
[8,9]
NS5B polymerase and NS5A protein . Each compound
or drug family induces a specific mutation profile that
may be characteristic of the viral genotype/subtype.
Furthermore, each class of DAA is characterized by a
difference in the genetic barrier to resistance. Even
though the specific resistance mutation for each
individual agent in the drug class differs, there is a

RESULTS
The Q80K variant in the NS3 gene was the most
prevalent mutation, being found in 44.66% of subtype
1a and 0.25% of subtype 1b. Other frequent mutations
observed in more than 2% of the NS3 sequences
were: I170V (3.21%) in genotype 1a, and Y56F
(15.93%), V132I (23.28%) and I170V (65.20%) in
genotype 1b. For the NS5A, 2.21% of the genotype
1a sequences have the P58S mutation, 5.95% of
genotype 1b sequences have the R30Q mutation,
15.79% of subtypes 2a sequences have the Q30R
mutation, 23.08% of subtype 2b sequences have a
L31M mutation, and in subtype 3a sequences, 23.08%
have the M31L resistant variants. For the NS5B, the
V321L RAV was identified in 0.60% of genotype 1a
and in 0.32% of genotype 1b sequences, and the
N142T variant was observed in 0.32% of subtype
1b sequences. The C316Y, S556G, D559N RAV were
identified in 0.33%, 7.82% and 0.32% of genotype 1b
sequences, respectively, and were not observed in other
genotypes.
CONCLUSION
HCV mutants resistant to DAAs are found in low
frequency, nevertheless they could be selected and
therapy could fail due resistance substitutions in HCV
genome.
Key words: hepatitis C virus resistance; quasispecies;
direct antiviral agents; polymorphisms; drug resistance
© The Author(s) 2016. Published by Baishideng Publishing
Group Inc. All rights reserved.

Core tip: Chronic hepatitis C virus (HCV) infection is
a significant cause of morbidity and mortality. The
main therapeutic targets are the NS3/4A protease,
NS5B polymerase, and NS5A replication complex.
Pre-existence of resistance associated variants to
direct antiviral agents (DAA) reduces sustained
virologic response rates. Despite the low frequency
of mutations, this resistant population is likely to be
selected in patients undergoing therapy with DAA.
Even though HCV variants resistant to DAA targeting
one viral protein remain susceptible to DAA targeting
another viral protein, combination therapy could fail
due to selection of HCV with resistance substitutions in
multiple targets.
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great concern about the possibility of cross-resistance
between compounds in the same inhibitor class,
[10]
especially for the NS3 protease and NS5A inhibitors .
The ability to detect RAV depends primarily on
the different types of the sequencing technologies
used, including population-based sequencing, clonal
sequencing and deep sequencing. The sensitivities for
detection by these three approaches were reported to
be approximately 25%, 5% and 0.5%, respectively,
and the presence of viral mutants below the detection
[11]
levels might be missed . For HCV the frequency
of routine testing of drug resistance prior to the use
of the new treatment regimens is not known. Some
[4]
guidelines suggest that routine monitoring for HCV
drug resistance-associated variants during therapy
should not be recommended and there is no consensus
on the utility of pre-treatment resistance testing.
Currently, there is a large number of HCV sequ
ences available on public databanks, however they
have not been analyzed to correlate HCV genotypes
and viral genomic characteristics with drug resistance
[11]
phenotypes . Three HCV databases are currently
available to provide insight into the basic biology,
immunology, and evolution of the virus: the Japanese
database (http://s2as02.genes.nig.ac.jp), the
European database (http://euhcvdb.ibcp.fr) and the
American database (Los Alamos National Laboratory)
(http://hcv.lanl.gov).
The objective of this study is to evaluate the
occurrence of polymorphisms and resistant mutations
in the NS3, NS5A and NS5B regions in treatment-naïve
HCV sequences deposited in the European hepatitis C
virus database (euHCVdb). This analysis will provide
insights into the levels of circulating drug resistance,
which may affect the success of the therapeutic
regimens.

prevalence and presence in drug trials, specifically
genotype 1 with protease inhibitors (PI) and genotype
3 with polymerase inhibitor. Reference strains for the
three genotypes were obtained (1a: AF009606, 1b:
D90208, 2a: D00944, 2b: D10988 and 3a: D17763).
Sequences containing missing data, such as gaps
and sequencing errors, and sequences from patients
previously treated with DAA were excluded from
the analysis. To ensure the quality of the analysis,
sequences with stop codons in the NS5B gene or
with ambiguities consisting of more than 2 bases per
nucleotide position or more than 2 ambiguities per
codon at individual drug resistance-associated position
were also excluded.

Alignment and edition of the sequences

The sequence alignment was performed with MEGA
[13]
6.06 MAC
followed by sequence editing, exclusion
of sequences with missing data, and translation of
the nucleic acids sequences into amino acids. The
resulting protein sequences were then analyzed using
BioEdit 7.2.5. to identify mutations associated with
[14]
resistance .

Analysis of natural polymorphisms

Known mutations associated with resistance to
protease-, NS5A complex- and polymerase-inhibitors
were used to search for polymorphism patterns among
[15]
HCV genotypes . Only positions that have been
described as being associated with failure in treatment
in in vivo studies, and/or as conferring a more than
2-fold change in replication in comparison to the
wildtype reference strain in in vitro phenotypic assays
were included in the analysis.

RESULTS
Database search

MATERIALS AND METHODS

The search resulted in 831 NS3, 869 NS5A and 6,065
NS5B sequences from HCV genotypes 1a, 1b, 2a, 2b
and 3a. After the exclusion of incomplete sequences
and those containing errors and/or gaps, and from
patients previously treated with DAA, 798 sequences
were included in the NS3 dataset. There were 313
from genotype 1a, 412 from genotype 1b, 19 from
genotype 2a, 26 from genotype 2b and 28 from
genotype 3a. There were 699 sequences identified
in the NS5A dataset, with 272 from genotype 1a,
353 from genotype 1b, 19 from genotype 2a, 26
from genotype 2b and 29 from genotype 3a. For the
NS5B polymerase there were 535 HCV sequences:
165 from genotypes 1a, 307 from genotype 1b, 19
from genotype 2a, 24 from genotype 2b and 20 from
genotype 3a. Notably, the NS5B region has more
than 5300 incomplete sequences deposited into this
databank.

HCV database

The sequences were downloaded from the euHCVdb
(https://euhcvdb.ibcp.fr/euHCVdb/). This bank
provides important data about the HCV sequences
(e.g. genotype, genomic region, viral proteins and
their functions, known 3-dimensional structures) and
ensures consistency of the annotations, which enables
reliable keyword queries. Users can extract subsets of
sequences obtained by Sanger sequencing matching
particular criteria or enter their own sequences and
analyze them with various bioinformatics programs
available on the same server. The euHCVdb is mainly
oriented towards protein sequence, structure and
function analyses and structural biology of HCV, and is
re-built every month from an up-to-date database by
[12]
an automated process .
The search was performed for full-length NS3
protease, NS5A and NS5B polymerase sequences of
HCV separated by genotypes 1a, 1b, 2a, 2b and 3a.
These subtypes were chosen due to their worldwide
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Table 1 Main amino acid substitutions found in the hepatitis C virus NS3 protease

1a
Position
36
80
155
156
168

wt
V (98.08)
Q (54.37)
R (99.36)
A (100)
D (99.36)

Variants
L (1.6)
M (0.32)
K (44.66) R (0.97)
K (0.64)
E (0.32)
G (0.32)

wt
L (0.74)
Q (93.37)
R (99.50)
A (100)
D (98.77)

Amino acid (frequency %)
HCV genotype
1b
2a
Variants
wt
Variants
I (0.25)
V (99.01)
L (100)
K (0.25)
L (6.39)
G (100)
P (0.50)
R (100)
A (100)
A (0.25)
E (0.98)
D (100)
-

2b
wt
L (100)
G (100)
R (100)
A (100)
D (100)

3a
Variants
-

wt
L (100)
Q (100)
R (100)
A (100)
Q (100)

Variants
-

Amino acids in bold are associated with resistance. wt: Wild-type; HCV: Hepatitis C virus.

in our dataset. Mutations L23M (0.37%), M28T (0.75%),
Q30H (1.47%), Q30R (0.37%), L31M (1.12%), P58S
(2.21%) and Y93C (0.37%) were observed, whereas
no variants were observed at NS5A position 32. Of
the 353 subtype 1b sequences analyzed, 0.28% had
the L23I mutation, 2.27% had L28M mutation, 5.95%
had R30Q mutation, 3.40% had M31L mutation,
3.68% had P58S mutation, and 4.25% had the Y93H
mutation. Of 19 subtype 2a sequences analyzed, one
(5.26%) sequence had the Q30R mutation, 3 (15.79%)
sequences had the M31L mutation, and one (5.26%)
sequence had the H58P mutation. For subtype 2b a
total of 26 sequences were analyzed, 6 (23.08%) with
the L31M and one (3.85%) with the S58P mutation. In
subtype 3a, for which 28 sequences were analyzed, the
resistant variants M28I, A30L and P58R were found,
each in a different sequence (3.57%) of the dataset.
Only M31L was found in more than one sequence
(23.08%) for this subtype. No mutation was found in
the NS5A sequence at position 32 of any subtype.

where resistance-associated amino acid substitutions
have been described in the literature for conferring
resistance to DAA. Amino acid substitutions related to
HCV resistance to DAA are described below.

Frequency of resistance-associated variants

NS3/4A PI (Table 1): The available PI are more
effective against HCV genotype 1 than to other
genotypes due to natural polymorphisms in the NS3
region of the latter, therefore they are only used in
the treatment of patients carrying HCV genotype 1.
Thus, our analysis discusses mainly the findings for
the genotype 1 dataset; nevertheless, the results for
the other genotypes are shown in Table 1. The Q80K
variant was the most prevalent mutation, found in
44.66% of the subtype 1a, and in 0.25% of subtype
1b sequences; the variant V80L was also observed in
6.39% of the latter. Other positions with frequencies
higher than 2% were I170V (3.21%) in genotype
1a, and Y56F (15.93%), V132I (23.28%) and I170V
(65.2%) in genotype 1b.
The V36L and V36M RAVs were identified in 1.6%
and 0.32% of genotype 1a sequences, respectively,
and in 0.74% and 0% of genotype 1b, respectively.
The T54S variant was observed in 0.97% of genotype
1a and in 0.5% of genotype 1b sequences. The
R155K variant was observed in 0.64% of genotype
1a sequences and was not observed in genotype
1b. There were two genotype 1b sequences (0.5%)
with P substitution at position 155. Finally, no RAV
A156T mutation was found in the 831 NS3 sequences
analyzed.
The prevalence of resistant variants for the PI
was found to be low in the dataset. Amino acid
substitutions conferring resistance to these drugs
were observed at NS3 position 168; the most frequent
mutation was D168E, which was found in 0.32% of
subtype 1a and in 0.98% of subtype 1b sequences.
The prevalence of known NS3 variants enriched for by
GZR was found to be low: F43S (0.31%) and Y56H
(0%) in the whole dataset; the NS3 Q41R mutation
was not observed.

NS5B polymerase inhibitors (Table 3): The NS5B
S96T, C223H/Y, and S282T variants were not observed
in any sequence in the present study, and the NS5B
N142T variant was observed in 0.32% of the subtype
1b sequences. The V321L RAV was identified in 0.6%
of genotype 1a sequences and in 0.32% of genotype
1b sequences.
The C316Y, S556G, and D559N RAVs were identified
in 0.33%, 7.82% and 0.32% of genotype 1b sequences,
respectively, and were not observed in other genotypes.
The M414T and Y448H RAVs were not found in any of
the 535 NS5B sequences analyzed.
Variants at NS5B positions 495 and 496 known
to confer resistance polymerase inhibitors were not
observed; on the other hand, the NS5B A421V and
V499A substitutions were found in both subtypes 1a
and 1b. The A421V mutation occurred in 9.64% of
subtype 1a and in 4.55% of subtype 1b sequences.
The V499A variant was the dominant amino acid
substitution in subtype 1a sequences (95.15%), while
for subtype 1b it was observed in only 9.74% of the
sequences; there has been no reported evidence for
negative clinical impact of the V499A.

NS5A replication complex inhibitors (Table 2): For
subtype 1a there were a total of 272 NS5A sequences

WJG|www.wjgnet.com
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wt
M
Q
L
Y

94.38
98.16
98.88
98.90

I
H
M
C

0.37
1.47
1.12
0.37

1a

0.75
0.37

0.74

T
R

H

V

4.49

wt
L
R
L
Y
97.17
92.35
96.03
95.75

M
K
M
H

2.27
1.13
3.40
4.25

WJG|www.wjgnet.com
1b
V
L/M
I

0.52
0.28
0.57
Q

5.95

wt
F
K
M
Y

Amino acid (frequency %)
HCV genotype

100
94.74
84.21
100

2a

R
L

5.26
15.79

wt
L
K
M
Y
100
100
76.92
100

2b

L

23.08

wt
M
A
L
Y
96.46
96.46
100
100

3a
I
L

3.57
3.57

The resistance to direct antiviral therapy has been a major problem in a number of chronic viral infections. While much attention has been given to studies about HIV
[16]
infection and resistance to antiviral therapy , the extent of mutations in the development of drug resistance in infection by HCV is less studied. The presence of HCV
mutations is mainly due to factors such as selection pressure, error-prone replication (because of RNA polymerase’s poor fidelity) and the high replication capacity of
[17]
the virus. It is believed that any mutant can be generated continuously in a HCV-infected patient . Hence, selected variants are considered to be pre-existent mutants
generated during the natural HCV life cycle. The incidence of resistant variants is variable and depends on the binding domain, as well as on the different HCV popu
lations, genotypes and subtypes.
With the exception of NS5B nucleoside analogues, the current DAAs target the NS3, as well as the allosteric sites of NS5B and NS5A, which all have a low threshold
[10,18]
of resistance
. Data from both replicon analysis and from clinical trials have consistently identified viral mutations that can be associated with antiviral treatment
[19]
[20]
failure . A recently published analysis found that 58.7% of the HCV sequences deposited in GenBank harbored at least one dominant resistance variant . In the
present study, the overall prevalence of patients with variants resistant to DAAs was found to be low.
The frequency of variants resistant to NS5A-inhibitors ranged from 0% to 4.25%. Variants resistant to polymerase-inhibitors were observed mainly in genotype 1b
and occurred in up to 7.82% (palm site), 2.41% (thumb site), and 9.74% (finger-loop site) of the sequences. These data corroborate other studies reported in the
[15,21]
[11]
literature
, and a comparasion with an analysis performed in Los Alamos databank showed similar results (Table 4).
Pre-existing dominant resistance mutations in the NS3 region are more common in treatment-naïve patients infected with genotype 1a (cumulative incidence 8.6%
[22]
vs 1.4%) . Within NS3, the resistant Q80K mutation, which is based on available data only relevant for SMV and ASV, was the most prevalent (44.66% genotype 1a,
[1,23]
0.25% genotype 1b) and this result corroborates the recent findings of Pol et al
with European patients where, Q80K was observed in 34.7% and 2.1% of subtype
1a and 1b patients, respectively. The mutation I170V, present in 3.21% of genotype 1a and 65.20% of the genotypes 1b sequences analyzed, has been reported as not
[24]
showing any influence on protease inhibitor activity . Therefore, considering the actual recommendations in EASL and AASLD guidelines, up to 45% of patients with
genotypes 1 have resistance mutations that can lead to treatment failure using PI.
The prevalence of resistant variants in the context of the NS5A inhibitors is highly dependent on viral subtype due to several positions having different baseline
[15]
amino acids in each subtype . Resistance against DVC, OMV, LDV is more common in genotype 1b (up to 4.25% of the sequences), but it can also occur in genotype
1a in less than 1.5% of the sequences. Furthermore, a broad cross-resistance between NS5A inhibitors is expected by the selection of mutations at codons 31 and/or
[24]
93 causing a loss in susceptibility to the majority of these compounds . Other researchers also determined Y93H as most frequent baseline NS5A RAV in genotype
[24,25]
1b (6%-23%), followed by L31M (3%-4%)
, whereas NS5A RAVs occurred at low frequencies in genotype 1a. Across the HCV genotypes, variation is observed at
several of the residues identified as important sites for resistance, and substitutions M28L, Q30R, H58P that were found in genotype 1b; M28F, Q30K, L31M, H58P in
genotype 2a; M28L, Q30K, L31M, H58P in genotype 2b and Q30A in genotype 3a could be defined as natural polymorphisms that distinguish those genotypes from 1a.

DISCUSSION

Amino acids in bold are associated with resistance. wt: Wild-type; HCV: Hepatitis C virus.

Position
28
30
31
93

Table 2 Main amino acid substitutions found in the hepatitis C virus NS5A protease
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Table 3 Main amino acid substitutions found in the hepatitis C virus NS5A protease
Amino acid (frequency %)
HCV genotype
1b

1a
Position
282
316
556

wt
S
C
S

99.40

R

0.60

wt
S
N
N

37.02
89.24

C
D

62.34
0.98

R/Y
G

0.32
7.82

N

1.95

2a
wt
S
C
G

2b
wt
S
C
G

3a
wt
S
C
G

Amino acid in bold are associated with resitance. wt: Wild-type; HCV: Hepatitis C virus.

Table 4 Resistance associated variants conferring resistance to direct antiviral agents

1

euHCVdb
DAA
NS3
Simeprevir

Paritaprevir
Grazoprevir
NS5A
Ledipasvir

Daclatasvir

Ombitasvir
Elbasvir

NS5B
Sofosbuvir
Dasabuvir

1a
RAV

Los Alamos
1b
RAV

1a
RAV

1b
RAV

V36M (0.32%)
Q80K (44.66%)
S122G (4.49%)
R155K (0.64%)
D168E (0.32%)

D168E (0.98%)

V36M (0.44%)
Q80K (36.62%)
n.a
R155K (0.88%)
D168E (0.29%)

R155K (0.64%)
D168E (0.32%)
A156T (0.00%)
D168E (0.32%)

D168E (0.98%)
A156T (0.00%)
D168E (0.98%)

R155K (0.88%)
D168E (0.29%)
A156T (0.00%)
D168E (0.29%)

D168E (0.80%)
A156T (0.00%)
D168E (0.80%)

n.a

n.a

n.a

n.a

n.a

n.a

S282T (0.00%)

S282T (0.00%)
C316N (36.17%)
C316Y (0.30%)
N556G (8.21%)

M28T (0.75%)
Q30H (1.47%)
Q30R (0.37%)
L31M (1.12%)
Y93H (0.74%)
Y93C (0.37%)
M28T (0.75%)
Q30H (1.47%)
Q30R (0.37%)
Y93H (0.74%)
M28V (4.49%)
Q30H (1.47%)
L31M (1.12%)
Y93H (0.74%)
S282T (0.00%)

Q80L (6.39%)
S122G (9.07%)

Q80L (6.02%)
n.a
D168E (0.80%)
D170T (0.20%)

Y93H (4.25%)

Y93H (4.25%)
Y93H (4.25%)

Y93H (4.25%)
S282T (0.00%)
C316N (37.02%)
C316Y (0.32%)
N556G (7.82%)

N556G (0.42%)

1

DAAs recommended by the EASL and AASLD guidelines 2015. RAV: Resistance associated variants; DAAs: Direct antiviral agents; AASLD: American
Association for the Study of Liver Diseases.

In contrast to NS3 PI, NS5B-non-nucleosideinhibitors and NS5A-inhibitors where resistance
mutations are subtype-dependent, little is known
about NS5B nucleos(t)ide analogs genotype- and
subtype-dependent resistance mutations. Several
nucleotide analogs have shown very promising
results and SOF is the first DAA in this drug class to
[9,26]
gain regulatory approval
, followed by DSV. In the
present analysis, NS5B RAV were not detected in
genotype 1a, whereas in genotype 1b, NS5B RAV were
found in more than one third of the individuals (C316N
in 37.02% and S556G in 7.82%) conferring low to
medium resistance to DSV. In mixed cohorts consisting
of American and European patients, while the S556G
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mutation was observed in frequencies of 0.5%-16%,
the C316N RAVs occurred in frequencies lower than
that observed in this study (11%-18%), at baseline in
[15]
genotype 1b samples .
The S282T is the in vitro signature resistance
mutation that conveys decreased susceptibility to
SOF in the replicon system. Although the S282T
substitution requires only a single nucleotide change,
this variant was not found in any of the NS5B
sequences analyzed in this study, neither in a previous
study based on sequences from the Los Alamos
[11]
databank ; in a study that analyzed 1459 HCV
sequences from GenBank, this mutation was found in
[20]
only one sequence .
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therapy, the extent of mutations in the development of drug resistance in HCV
infection is less studied. The presence of HCV mutations is mainly due to
factors such as selection pressure, error-prone replication (because of RNA
polymerase’s poor fidelity) and the high replication capacity of the virus. It
is believed that any mutant can be generated continuously in HCV-infected
patients. Hence, selected variants are considered to be pre-existent mutations
generated during the natural HCV life cycle. The incidence of resistant variants
is variable and depends on the binding domain, as well as on the different
HCV populations, genotypes and subtypes and pre-existence of resistance
associated variants to direct antiviral agents (DAAs) reduces sustained
virologic response rates. A recently published analysis found that 58.7% of the
HCV sequences deposited in the GenBank harbored at least one dominant
resistance variant.

With the currently in-use DAAs recommended by
EASL and AASLD guidelines, our analyses suggest that
it is possible that virologic failure could occur in half of
the patients with HCV genotype 1a receiving SMV in
combinations with pegylated-intereferon and ribavirin.
In addition, more than 7% of the patients with HCV
genotype 1b receiving DSV could also fail to respond to
treatment, and the presence of variants with resistant
mutations in the NS5A region should affect almost 5%
of the treated individuals.
If in one hand the analysis of a public databank
may not reflect the real prevalence of RAV in the
population, on the other hand the abundance of infor
mation deposited in databank’s sequences allows the
identification of potentially unknown polymorphisms
in populations not submitted to new HCV treatments.
Since it is impossible to correlate criteria of inclusion
in databanks with population data, epidemiological
studies are necessary to determine the real prevalence
of RVA in the population.
Although the potential to confer resistance to
DAAs of the majority of the amino acid substitutions
identified in our analyses is not known, the ability of
HCV to rapidly evolve under drug selection pressure
and the presence of baseline natural polymorphisms
associated with resistance to DAA should be considered
as possible threats to the success of these new
therapies. The real impact of these constitutive RAV
on the possibility of SVR with DAA remains unclear
and undefined and some of these RAV apparently
disappear after therapy (NS3/NS4 RAV) while others
remain in the viral population (NS5 RAV). Globally,
clinical significance of these constitutive RAV remains
obscure
In summary, there are many relevant clinical ques
tions that still need to be answered regarding HCV
resistance to DAAs, mainly due to the limited available
data and the large number of DAA approved or soon
to be approved for clinical use. Perhaps resistance
mutations in the new interferon-free DAA era may not
[27,28]
have significant clinical impact initially
, nonetheless
the presence of a minor drug-resistance population
will likely affect the success of the therapy upon the
expansion and prolonged use of DAA regimens, and
the relevance of pre-existing resistance mutations for
responses to Interferon-free DAA therapies needs to
be further investigated. Therefore, testing for drug
resistance variants prior to the initiation of treatment
will be needed in the very near future in order to help
guide the selection of the most optimized treatment
option.

Research frontiers

It is expected that in the near future a method able to detect all the mutations in
the HCV genome will be available, making it possible to decide which DAA can
be used to treat hepatitis C in a specific patient.

Innovations and breakthrough

This study showed a low frequency of mutations but a high number of
polymorphisms of HVC genome which can impact in patients receiving
treatment with DAAs.

Applications

Although the potential to confer resistance of the majority of the amino acid
substitutions identified in our analyses is not known, the ability of HCV to rapidly
evolve under drug selection pressure and the presence of baseline natural
polymorphisms associated with resistance to DAAs should be considered as
possible threats to the success of these new therapies.

Peer-review

This manuscript analyzed the occurrence of polymorphisms and resistant
mutations in NS3, NS5A and NS5B regions in treatment-naive HCV sequences
deposited in the European hepatitis C virus database.
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